celecoxib and arsenic

celecoxib has been researched along with arsenic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amirheidari, B; Ghahremani, MH; Mandegary, A; Seyedabadi, M; Sharif, E; Torshabi, M1
Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X1

Other Studies

2 other study(ies) available for celecoxib and arsenic

ArticleYear
Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
    BioMed research international, 2013, Volume: 2013

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Lung Neoplasms; MAP Kinase Signaling System; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; RNA, Messenger; Sulfonamides; Time Factors

2013
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celecoxib; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; p38 Mitogen-Activated Protein Kinases; Stomach Neoplasms; Sulfides; Triazoles; Tumor Suppressor Protein p53

2015